Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden
暂无分享,去创建一个
Magda Tsolaki | Bruno Vellas | Andrew Simmons | Eric Westman | Hilkka Soininen | Stephen Newhouse | Patrizia Mecocci | Iwona Kloszewska | Madhav Thambisetty | Simon Lovestone | Michelle K. Lupton | Abdul Hye | S. Newhouse | A. Simmons | H. Soininen | E. Westman | P. Mecocci | B. Vellas | M. Tsolaki | I. Kloszewska | S. Lovestone | M. Lupton | K. Lunnon | S. Kiddle | Caroline Johnston | M. Ward | M. Thambisetty | A. Hye | R. Dobson | I. Pike | Caroline Johnston | Malcolm Ward | Ian Pike | Steven John Kiddle | Joanna Riddoch-Contreras | Michelle Katharine Lupton | Katie Lunnon | Richard Dobson | J. Riddoch-Contreras | Richard J. B. Dobson | Abdul Hye
[1] A. Simmons,et al. MRI Measures of Alzheimer's Disease and the AddNeuroMed Study , 2009, Annals of the New York Academy of Sciences.
[2] Ulrike Groemping,et al. Relative Importance for Linear Regression in R: The Package relaimpo , 2006 .
[3] T. Glass,et al. Apolipoprotein e genotype, cortisol, and cognitive function in community-dwelling older adults. , 2008, The American journal of psychiatry.
[4] Susan M Resnick,et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.
[5] Christos Davatzikos,et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment , 2012, NeuroImage.
[6] Eric Westman,et al. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion , 2012, NeuroImage.
[7] Guanghua Xiao,et al. A serum protein-based algorithm for the detection of Alzheimer disease. , 2010, Archives of neurology.
[8] A. Drzezga,et al. Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.
[9] Yi Zhang,et al. Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease , 2011, PloS one.
[11] Ron Kohavi,et al. A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection , 1995, IJCAI.
[12] Nick C Fox,et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.
[13] Magda Tsolaki,et al. The AddNeuroMed framework for multi‐centre MRI assessment of Alzheimer's disease : experience from the first 24 months , 2011, International journal of geriatric psychiatry.
[14] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[15] Todd E. Golde,et al. Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.
[16] H. Middelkoop,et al. Plasma cortisol and norepinephrine in Alzheimer’s disease: opposite relations with recall performance and stage of progression , 2007, Acta Neuropsychiatrica.
[17] A. Hofman,et al. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study , 1998, Neuroscience Letters.
[18] Norman Relkin,et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease , 2003, Neurochemistry International.
[19] H. Arai,et al. Serum amyloid P component level in Alzheimer's disease. , 1996, Dementia.
[20] A. Simmons,et al. AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease , 2009, Annals of the New York Academy of Sciences.
[21] Berislav V. Zlokovic,et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.
[22] Zina M. Ibrahim,et al. Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. , 2012, Journal of Alzheimer's disease : JAD.
[23] A. M. Szczepanik,et al. IL-4, IL-10 and IL-13 modulate Aβ(1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line , 2001, Journal of Neuroimmunology.
[24] G. Siest,et al. Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study , 2000, Clinical chemistry and laboratory medicine.
[25] Walter J Koroshetz,et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. , 2012, Archives of neurology.
[26] C. Lemere,et al. Complement C3 Deficiency Leads to Accelerated Amyloid β Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice , 2008, The Journal of Neuroscience.
[27] C. Exley,et al. Serum amyloid P component accelerates the formation and enhances the stability of amyloid fibrils in a physiologically significant under-saturated solution of amyloid-β42. , 2012, Journal of Alzheimer's disease : JAD.
[28] Marilyn S. Albert,et al. Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators. , 2004, Alzheimer disease and associated disorders.
[29] T. J. Grabowski,et al. Proteome-based plasma biomarkers for Alzheimer's disease , 2007 .
[30] L. Ferrucci,et al. Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. , 2011, Journal of Alzheimer's disease : JAD.
[31] W. Jagust,et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.
[32] M. Weiner,et al. Relationships between biomarkers in aging and dementia , 2009, Neurology.
[33] Regina Berretta,et al. Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset , 2012, PloS one.
[34] Deborah Pinchev,et al. Mining biomarkers in human sera using proteomic tools , 2004, Proteomics.
[35] Guanghua Xiao,et al. A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI , 2011, PloS one.
[36] R. Maccioni,et al. Interleukin-3 prevents neuronal death induced by amyloid peptide , 2007, BMC Neuroscience.
[37] H. Soininen,et al. PET Amyloid Ligand [11C]PIB Uptake and Cerebrospinal Fluid β-Amyloid in Mild Cognitive Impairment , 2008, Dementia and Geriatric Cognitive Disorders.
[38] T. Wetterling,et al. Serum α1-antitrypsin and α2-macroglobulin in Alzheimer's and Binswanger's disease , 1994, The clinical investigator.
[39] C. Rowe,et al. Plasma apolipoprotein E and Alzheimer disease risk , 2011, Neurology.
[40] C. Jack,et al. MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.
[41] L. Schneider,et al. Report of the task force on designing clinical trials in early (predementia) AD , 2010, Neurology.
[42] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[43] L. Tiret,et al. Polymorphisms of the apolipoprotein B and E genes and their relationship to plasma lipid variables in healthy Chinese men , 1993, Human Genetics.
[44] P. Sen,et al. Introduction to bivariate and multivariate analysis , 1981 .
[45] Eileen Daly,et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease , 2008, Journal of Neurology.
[46] C. Jack,et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects , 2010, Alzheimer's & Dementia.
[47] Justin Bedo,et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.
[48] J. Wands,et al. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. , 2005, Journal of Alzheimer's disease : JAD.
[49] Kewei Chen,et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.
[50] Steven J. Greco,et al. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. , 2009, Biochemical and biophysical research communications.